PDE10A, which was recently validated as a novel target to treat pulmonary arterial hypertension (PAH) due to its central role in progressive pulmonary vascular remodeling39,40, was identified as a target of baricitinib. Here, PDE10A is linked to pulmonary arterial hypertension.